ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で81.46%の成長率を示しています。
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 883.37Mです。
黒字転換
同社は黒字転換を果たし、最新の年間純利益はUSD です。
適正水準
同社の最新のPEは19.26で、過去3年間の水準と比較して適正圏にあります。
機関投資家の買い増し
最新の機関投資家の保有株数は23.15M株で、前四半期比で0.25%増加しています。
ジョン・ハスマンが保有
スター投資家ジョン・ハスマンは本銘柄を49.41K株保有しています。